Increase in the number of shares granted

No definition available.

Name:	clls_IncreaseInTheNumberOfSharesGranted
Namespace Prefix:	clls_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Non-cash stock based compensation expense due to change in ratio conversion.

+ References

No definition available.

+ Details

Name:	clls_NonCashStockBasedCompensationExpenseDueToChangeInRatioConversion
Namespace Prefix:	clls_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The option life of share option granted.

+ References

No definition available.

+ Details

Name:	clls_OptionLifeShareOptionGranted
Namespace Prefix:	clls_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Option vesting period.

+ References

No definition available.

+ Details

Name:	clls_OptionVestingPeriod
Namespace Prefix:	clls_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of fair market value.

+ References

No definition available.

+ Details

Name:	clls_PercentageOfFairMarketValue
Namespace Prefix:	clls_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Vesting period, share-based payment arrangements.

+ References

No definition available.

+ Details

Name:	clls_VestingPeriodShare-BasedPaymentArrangements
Namespace Prefix:	clls_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 2
-IssueDate 2025-01-01
-Paragraph 51
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_51_a&doctype=Standard
-URIDate 2025-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 34
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_34_a&doctype=Standard
-URIDate 2025-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 34
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_34_a&doctype=Standard
-URIDate 2025-03-27

+ Details

Name:	ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Note Expiry date 2027-01-01
-Name IAS
-Number 1
-IssueDate 2025-01-01
-Paragraph 112
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard
-URIDate 2025-03-27

+ Details

Name:	ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2025-01-01
-Paragraph 24
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard
-URIDate 2025-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2025-01-01
-Paragraph B16
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B16&doctype=Appendix&subtype=B
-URIDate 2025-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 89
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_89&doctype=Standard
-URIDate 2025-03-27

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 89
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_89&doctype=Standard
-URIDate 2025-03-27

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Note Expiry date 2027-01-01
-Name IAS
-Number 1
-IssueDate 2025-01-01
-Paragraph 54
-Subparagraph e
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_e&doctype=Standard
-URIDate 2025-03-27

+ Details

Name:	ifrs-full_InvestmentAccountedForUsingEquityMethod
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IFRS
-Number 2
-IssueDate 2025-01-01
-Paragraph 45
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard
-URIDate 2025-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 2
-IssueDate 2025-01-01
-Paragraph 47
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard
-URIDate 2025-03-27

+ Details

Name:	ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:decimalItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of share options granted in a share-based payment arrangement.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 2
-IssueDate 2025-01-01
-Paragraph 45
-Subparagraph b
-Clause ii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_ii&doctype=Standard
-URIDate 2025-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 31
-Subparagraph b
-Clause ii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_ii&doctype=Standard
-URIDate 2025-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 31
-Subparagraph b
-Clause ii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_ii&doctype=Standard
-URIDate 2025-03-27

+ Details

Name:	ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:decimalItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of shares issued by the entity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Note Expiry date 2027-01-01
-Name IAS
-Number 1
-IssueDate 2025-01-01
-Paragraph 106
-Subparagraph d
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard
-URIDate 2025-03-27

+ Details

Name:	ifrs-full_NumberOfSharesIssued
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

The description of the rights, preferences and restrictions attaching to a class of share capital including restrictions on the distribution of dividends and the repayment of capital. [Refer: Classes of share capital [domain]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph B10
-Subparagraph a
-Clause v
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_v&doctype=Appendix&subtype=B
-URIDate 2025-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 160
-Subparagraph a
-Clause v
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_v&doctype=Standard
-URIDate 2025-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Note Expiry date 2027-01-01
-Name IAS
-Number 1
-IssueDate 2025-01-01
-Paragraph 79
-Subparagraph a
-Clause v
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_v&doctype=Standard
-URIDate 2025-03-27

+ Details

Name:	ifrs-full_RightsPreferencesAndRestrictionsAttachingToClassOfShareCapital
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	ifrs-full_CategoriesOfRelatedPartiesAxis=clls_CalyxtMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ClassesOfShareCapitalAxis=clls_PerformanceStockUnitMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CategoriesOfRelatedPartiesAxis=clls_AstraZenecaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=clls_StockOption1Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CategoriesOfRelatedPartiesAxis=clls_ExecutiveEmployeesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CategoriesOfRelatedPartiesAxis=clls_NonExecutiveEmployeesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=clls_FreeSharesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_RestrictedShareUnitsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_WarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ComponentsOfEquityAxis=clls_ClassAPreferredSharesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ComponentsOfEquityAxis=clls_ClassBPreferredSharesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Share-based payments - Additional Information (Details)							12 Months Ended
Share-based payments - Additional Information (Details)	Dec. 09, 2025 shares	Nov. 07, 2025 shares	Jun. 23, 2025 shares	Mar. 13, 2025 shares	Jan. 30, 2025 shares	May 03, 2024 USD ($) shares	Dec. 31, 2025 USD ($) shares	Dec. 31, 2024 USD ($) shares	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($)	Sep. 30, 2024 shares	May 28, 2024 shares	May 12, 2024 shares	Mar. 05, 2024 shares	Nov. 14, 2023 shares	Nov. 06, 2023 shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Option life, share option granted							10 years
Percentage of market value							100.00%
Number of shares issued \| shares											238	135,980	2,120	204,334		16,000,000
Conversion ratio							1 share to 1.06
Increase in the number of shares granted						6.00%
Additional stock-based compensation expense								$ 100,000
Number of other equity instruments granted in share-based payment arrangement \| shares							6,421,033
Calyxt [Member] \| Performance Stock Unit [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation expense									$ 300,000	$ 300,000
AstraZeneca [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Equity investment						$ 28,000,000
Stock options [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of equity instruments granted in share-based payment arrangement							6,346,033	3,054,163	1,835,411
Vesting period, years							4 years
Share-based compensation expense							$ 5,600,000	$ 2,600,000	$ 2,300,000
Stock options [member] \| Executive Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period, years			3 years		3 years
Number of equity instruments granted in share-based payment arrangement \| shares			270,500		3,851,783
Stock options [member] \| Non Executive Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period, years	4 years	4 years	4 years	4 years
Number of equity instruments granted in share-based payment arrangement \| shares	20,000	132,000	205,600	1,866,150
Stock options [member] \| Calyxt [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation expense									1,800,000
Free Shares [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period, years							3 years
Share-based compensation expense							$ 400,000	$ 500,000	$ 2,900,000
Number of other equity instruments granted in share-based payment arrangement \| shares							0	0	342,900
Restricted Stock Unit Awards [member] \| Calyxt [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation expense									$ 2,400,000
Warrants [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of equity instruments granted in share-based payment arrangement							75,000	0	0
Share-based compensation expense							$ 100,000	$ 0	$ 0
Class A Preferred Shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of shares issued \| shares						10,000,000									10,000,000
Class B Preferred Shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of shares issued \| shares						18,000,000									18,000,000